Cargando…

AT-101 Enhances the Antitumor Activity of Lenalidomide in Patients with Multiple Myeloma

SIMPLE SUMMARY: Bcl-2 family proteins play a key role in myeloma cell survival and are implicated in drug resistance and development of refractory disease, thus making them an attractive therapeutic target. Currently available strategies targeting Bcl-2 proteins in multiple myeloma have shown a bene...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ailawadhi, Sikander, Parrondo, Ricardo D., Dutta, Navnita, Han, Bing, Ciccio, Gina, Cherukuri, Yesesri, Alegria, Victoria R., LaPlant, Betsy R., Roy, Vivek, Sher, Taimur, Edwards, Brett, Lanier, Stephanie, Manna, Alak, Heslop, Keisha, Caulfield, Thomas, Maldosevic, Emir, Storz, Peter, Manochakian, Rami, Asmann, Yan, Chanan-Khan, Asher A., Paulus, Aneel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9857228/ https://www.ncbi.nlm.nih.gov/pubmed/36672426 http://dx.doi.org/10.3390/cancers15020477

Ejemplares similares

The digital divide: Racial disparities in adoption and utilization of health information technology among patients with lymphoid cancers
por: Ailawadhi, Sikander, et al.
Publicado: (2023)

Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting
por: Jayakrishnan, Thejus, et al.
Publicado: (2021)

Use of KRD-PACE as Salvage Therapy in Aggressive, Relapsed/Bortezomib-Refractory Extramedullary Multiple Myeloma: A Report of Two Cases and Literature Review
por: Parrondo, Ricardo D., et al.
Publicado: (2020)

RETRACTED ARTICLE: Subsequent anti-myeloma therapy after idecabtagene vicleucel treatment in patients with relapsed/refractory multiple myeloma: A single center analysis
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Updates in the Use of BCL-2-Family Small Molecule Inhibitors for the Treatment of Relapsed/Refractory Multiple Myeloma
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature
por: Baksh, Mizba, et al.
Publicado: (2021)

A Panel Evaluation of the Changes in the General Public’s Social-Media-Following of United States’ Public Health Departments during COVID-19 Pandemic
por: Khokhar, Areej, et al.
Publicado: (2021)

Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia
por: Kumar, Vivek, et al.
Publicado: (2019)

Myelomatous ascites and pleural effusion in relapsed multiple myeloma
por: Baksh, Mizba, et al.
Publicado: (2022)

Anti-B Cell Maturation Antigen Chimeric Antigen Receptor T Cell Therapy for the Treatment of AL Amyloidosis and Concurrent Relapsed/Refractory Multiple Myeloma: Preliminary Efficacy and Safety
por: Das, Saurav, et al.
Publicado: (2023)

Retreatment with obinutuzumab: An addition to the therapeutic landscape of chronic lymphocytic leukemia
por: Khurana, Sharad, et al.
Publicado: (2019)

Immunophenotyping of Waldenströms Macroglobulinemia Cell Lines Reveals Distinct Patterns of Surface Antigen Expression: Potential Biological and Therapeutic Implications
por: Paulus, Aneel, et al.
Publicado: (2015)

Iopofosine I-131 treatment in late-line patients with relapsed/refractory multiple myeloma post anti-BCMA immunotherapy
por: Longcor, Jarrod, et al.
Publicado: (2022)

Benchmarking of de novo assembly algorithms for Nanopore data reveals optimal performance of OLC approaches
por: Cherukuri, Yesesri, et al.
Publicado: (2016)

Trends in utilization of stored cryopreserved autologous peripheral hematopoietic cells intended for a second (or beyond) autologous hematopoietic cell transplantation in patients with multiple myeloma: a single center experience
por: Yassine, Farah, et al.
Publicado: (2023)

Targeted treatment for chronic lymphocytic leukemia
por: Masood, Aisha, et al.
Publicado: (2011)

Association of Race, Socioeconomic Factors, and Treatment Characteristics With Overall Survival in Patients With Limited-Stage Small Cell Lung Cancer
por: Zhou, Kexun, et al.
Publicado: (2021)

Survival of Black and White Patients With Stage IV Small Cell Lung Cancer
por: Shi, Huashan, et al.
Publicado: (2021)

Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment
por: Paulus, A, et al.
Publicado: (2017)

Prevention Of Skeletal Related Events In Multiple Myeloma: Focus On The RANK-L Pathway In The Treatment Of Multiple Myeloma
por: Parrondo, Ricardo D, et al.
Publicado: (2019)

HLA class-I and class-II restricted neoantigen loads predict overall survival in breast cancer
por: Ren, Yingxue, et al.
Publicado: (2020)

Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib
por: Hampel, Paul J., et al.
Publicado: (2022)

Second primary acute lymphoblastic leukemia in adults: a SEER analysis of incidence and outcomes
por: Swaika, Abhisek, et al.
Publicado: (2017)

Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia
por: Chitta, K, et al.
Publicado: (2014)

Phase 2 trial of Intravenously Administered Plerixafor for Stem Cell Mobilization in Patients with Multiple Myeloma Following Lenalidomide Based Initial Therapy
por: Kumar, Shaji K., et al.
Publicado: (2013)

Unique characteristics and outcomes of therapy-related acute lymphoblastic leukemia following treatment for multiple myeloma
por: Parrondo, Ricardo D., et al.
Publicado: (2022)

Variable risk of second primary malignancy in multiple myeloma patients of different ethnic subgroups
por: Ailawadhi, S, et al.
Publicado: (2014)

Practice Model: Establishing and Running an Oral Chemotherapy Management Clinic
por: May, Paige, et al.
Publicado: (2017)

P915: TREATMENT PATTERNS AND CLINICAL OUTCOMES OF PATIENTS WITH MULTIPLE MYELOMA PREVIOUSLY TREATED WITH LENALIDOMIDE AND AN ANTI-CD38 MONOCLONAL ANTIBODY: FINDINGS FROM THE CONNECT MM DISEASE REGISTRY
por: Abonour, Rafat, et al.
Publicado: (2023)

Trends in participant race and sex reporting in lung cancer phase III clinical trials
por: Aslam, Faaiq N., et al.
Publicado: (2023)

Survival trends among non‐small‐cell lung cancer patients over a decade: impact of initial therapy at academic centers
por: Lou, Yanyan, et al.
Publicado: (2018)

Lenalidomide versus lenalidomide + dexamethasone prolonged treatment after second‐line lenalidomide + dexamethasone induction in multiple myeloma
por: Lund, Johan, et al.
Publicado: (2018)

Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics
por: Razavi, P, et al.
Publicado: (2013)

Reframing the Value of Treatments for Relapsed/Refractory Multiple Myeloma
por: Ailawadhi, Sikander, et al.
Publicado: (2018)

Lenalidomide-Associated ITP
por: Herold, Christina I., et al.
Publicado: (2011)

Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER‐medicare analysis
por: Ailawadhi, Sikander, et al.
Publicado: (2017)

Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study
por: Desai, Sanjal H., et al.
Publicado: (2021)

Carfilzomib–lenalidomide–dexamethasone vs lenalidomide–dexamethasone in relapsed multiple myeloma by previous treatment
por: Dimopoulos, M A, et al.
Publicado: (2017)

Lenalidomide-associated B-cell ALL: clinical and pathologic correlates and sensitivity to lenalidomide withdrawal
por: Geyer, Mark B., et al.
Publicado: (2023)

Phase I safety data of lenalidomide, bortezomib, dexamethasone, and elotuzumab as induction therapy for newly diagnosed symptomatic multiple myeloma: SWOG S1211
por: Usmani, S Z, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_09snjbcd91fgeerda424dd6t9n